Optimer Pharmaceuticals (OPTR) Reports Q1 EPS of $1.04, Up $1.43 Y/Y
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Financial Fact:
Income (loss) from operations: -27.12M
Today's EPS Names:
TFS, PBNK, FNRN, More
Financial Fact:
Income (loss) from operations: -27.12M
Today's EPS Names:
TFS, PBNK, FNRN, More
Join SI Premium – FREE
Optimer Pharmaceuticals (NASDAQ: OPTR) reported Q1 EPS of $1.04, versus ($0.39) last year. Revenue for the quarter came in at $69.28 million, versus $297.44 thousand last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Pinnacle Bank (PBNK) Tops Q3 EPS by 4c
- TFS Financial (TFSL) Reports In-Line Q4 EPS
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
